Citryll BV
Oss, Netherlands
Renato Chirivi is co-founder as well as CTO of Citryll and previously CSO. He has been central in bringing Citryll to its current clinical develpment status. He is the co-inventor of anti-citrullinated histone antibodies (ACHA), antagonists of NET biology, and an expert on antibody discovery, engineering, production, and protein citrullination. He has numerous years of experience in cancer, neurobiology and molecular immunology which he gained at the Mario Negri Institute for Pharmacological Research in Italy, The Scripps research institute in California, USA, the Nijmegen Center for Molecular Life Sciences, and ModiQuest BV, the Netherlands. Renato is responsible for technology development, MoA programme of Citryll's NET antagonist, intellectual property and specific therapeutic areas.
Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): Citryll BV: Employee (Ongoing), Intellectual Property/Patents (Ongoing), Ownership Interest (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)
